flaura study of osimertinib versus tki for 1st line nsclc
Published 6 years ago • 207 plays • Length 6:21Download video MP4
Download video MP3
Similar videos
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
8:55
suresh ramalingam: osimertinib vs comparator egfr-tki 1st-line in egfrm advanced nsclc (flaura)
-
3:31
osimertinib suitable for first line egfrm lung cancer
-
5:42
osimertinib and the flaura trial
-
7:00
flaura trial: impact of os data in advanced nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
5:26
first-line osimertinib in egfr mutant ansclc patients: progression pattern and safety in the rea...
-
6:06
osimertinib, the standard for egfr nsclc
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
1:36
comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
9:36
the flaura trial: practice-changing results for egfr mutation-positive nsclc (bmic-007)
-
4:51
early returns on flaura trial: osimertinib as first line agent in egfr mut-pos. nsclc? (bmic-002)
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
7:45
upfront use of osimertinib in egfr nsclc
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
5:52
mechanisms of osimertinib resistance in aura 3
-
9:27
post-hoc analysis of sequential afatinib and osimertinib in nsclc patients